Clinical trial
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
NCT00179478 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00179478 |
|---|---|
| Title | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis |
| Official title | Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) |
| Acronym | CHAMPIONS10 |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome |
| Intervention type | Drug |
| Interventions | interferon beta 1a 30 ug IM once weekly |
| Enrollment | 155 |
| Start date | Feb 1, 2001 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Sep 6, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: